Alimera Sciences, Inc. (ALIM)
NASDAQ: ALIM · IEX Real-Time Price · USD
3.650
+0.170 (4.89%)
May 3, 2024, 4:30 PM EDT - Market closed
Alimera Sciences Revenue
In the year 2023, Alimera Sciences had annual revenue of $80.75M with 49.19% growth. Revenue in the quarter ending December 31, 2023 was $26.31M with 87.51% year-over-year growth.
Revenue (ttm)
$80.75M
Revenue Growth
+49.19%
P/S Ratio
2.37
Revenue / Employee
$524,377
Employees
154
Market Cap
191.17M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 80.75M | 26.63M | 49.19% |
Dec 31, 2022 | 54.13M | -4.90M | -8.30% |
Dec 31, 2021 | 59.03M | 8.21M | 16.15% |
Dec 31, 2020 | 50.82M | -3.12M | -5.79% |
Dec 31, 2019 | 53.94M | 7.34M | 15.76% |
Dec 31, 2018 | 46.60M | 10.69M | 29.76% |
Dec 31, 2017 | 35.91M | 1.58M | 4.60% |
Dec 31, 2016 | 34.33M | 11.90M | 53.01% |
Dec 31, 2015 | 22.44M | 14.02M | 166.39% |
Dec 31, 2014 | 8.42M | 6.55M | 349.95% |
Dec 31, 2013 | 1.87M | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Semler Scientific | 68.18M |
908 Devices | 50.23M |
CVRx, Inc. | 39.30M |
MediWound | 18.69M |
Profound Medical | 5.41M |
ALIM News
- 6 weeks ago - Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network - GlobeNewsWire
- 2 months ago - Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results - GlobeNewsWire
- 3 months ago - The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN® - GlobeNewsWire
- 4 months ago - Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 months ago - Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 months ago - Alimera Appoints Maggie A. Pax to Its Board of Directors - GlobeNewsWire
- 6 months ago - Alimera Sciences Reports Third Quarter 2023 Results - GlobeNewsWire
- 7 months ago - Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress - GlobeNewsWire